ezetimibe
FDA Approved
Description
Ezetimibe is a cholesterol absorption inhibitor that reduces intestinal absorption of dietary and biliary cholesterol. It is used as adjunctive therapy in Schnyder corneal dystrophy to manage systemic hyperlipidemia and potentially reduce corneal lipid deposition. It is often combined with statins for enhanced lipid-lowering effects.
Indications & Therapeutic Use
primary hypercholesterolemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia, Schnyder corneal dystrophy
Linked Diseases:
Schnyder corneal dystrophy
C535475
Global Availability (11 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
ezetimibe
| Generic Name | ezetimibe |
| Brands | 1 brand available |
| Active Ingredient | ezetimibe |
| Drug Class | primary hypercholesterolemia |
| Manufacturer | Merck |
| Dosage Forms | oral tablet 10mg |
| Medical Code | C10AX09 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 11 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations12 Validated Nodes